Literature DB >> 2594781

Sequential effects of interleukin 2-diphtheria toxin fusion protein on T-cell activation.

G Walz1, B Zanker, K Brand, C Waters, F Genbauffe, J B Zeldis, J R Murphy, T B Strom.   

Abstract

The interleukin 2-diphtheria toxin-related fusion protein (IL-2-toxin) rapidly inhibits protein synthesis in IL-2 receptor (IL-2R)-bearing phytohemagglutinin-activated T cells but transiently stimulates DNA synthesis. At 7 hr after interaction with IL-2R+ phytohemagglutinin-activated T cells, IL-2-toxin-treated cells bear augmented steady-state levels of c-myc, interferon gamma, and IL-2R mRNA; these effects are indistinguishable from those produced by recombinant IL-2. Amplification of IL-2 sequences by the polymerase chain reaction reveals an increased level of IL-2 mRNA in cell cultures treated with recombinant IL-2, IL-2-toxin, and cycloheximide. These results suggest that IL-2-toxin can affect de novo IL-2 gene transcription/mRNA stabilization through independent mechanisms exerted by both the IL-2R binding domain and ADP-ribosyltransferase activity of the fusion protein. After 20 hr of culture, IL-2R mRNA was markedly decreased in both IL-2-toxin- and cycloheximide-treated phytohemagglutinin-activated T cells. Although interaction of IL-2-toxin with IL-2R+ T cells initially mimics the stimulatory effects of IL-2 upon c-myc, interferon gamma, IL-2R, and IL-2 gene expression, the consequences of inhibition of protein synthesis mediated by the ADP-ribosyltransferase activity of the toxin dominate after 7 hr and are indistinguishable from those effects mediated by cycloheximide.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2594781      PMCID: PMC298521          DOI: 10.1073/pnas.86.23.9485

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  22 in total

1.  Genetic construction, expression, and melanoma-selective cytotoxicity of a diphtheria toxin-related alpha-melanocyte-stimulating hormone fusion protein.

Authors:  J R Murphy; W Bishai; M Borowski; A Miyanohara; J Boyd; S Nagle
Journal:  Proc Natl Acad Sci U S A       Date:  1986-11       Impact factor: 11.205

2.  Induction, suppression and superinduction of lymphokine mRNA in T lymphocytes.

Authors:  J Shaw; K Meerovitch; J F Elliott; R C Bleackley; V Paetkau
Journal:  Mol Immunol       Date:  1987-05       Impact factor: 4.407

3.  Interleukin 2-diphtheria toxin fusion protein can abolish cell-mediated immunity in vivo.

Authors:  V E Kelley; P Bacha; O Pankewycz; J C Nichols; J R Murphy; T B Strom
Journal:  Proc Natl Acad Sci U S A       Date:  1988-06       Impact factor: 11.205

4.  Inhibition of adenylate cyclase by IL 2 in human T lymphocytes is mediated by protein kinase C.

Authors:  S K Beckner; W L Farrar
Journal:  Biochem Biophys Res Commun       Date:  1987-05-29       Impact factor: 3.575

5.  Mechanisms regulating the level of IL-2 mRNA in T lymphocytes.

Authors:  J Shaw; K Meerovitch; R C Bleackley; V Paetkau
Journal:  J Immunol       Date:  1988-04-01       Impact factor: 5.422

6.  Interleukin 2 induces a rapid increase in intracellular pH through activation of a Na+/H+ antiport. Cytoplasmic alkalinization is not required for lymphocyte proliferation.

Authors:  G B Mills; E J Cragoe; E W Gelfand; S Grinstein
Journal:  J Biol Chem       Date:  1985-10-15       Impact factor: 5.157

7.  Cytotoxic activity of an interleukin 2-Pseudomonas exotoxin chimeric protein produced in Escherichia coli.

Authors:  H Lorberboum-Galski; D FitzGerald; V Chaudhary; S Adhya; I Pastan
Journal:  Proc Natl Acad Sci U S A       Date:  1988-03       Impact factor: 11.205

8.  Interleukin 2 and a lactogen regulate proliferation and protein phosphorylation in Nb2 cells.

Authors:  E J Rayhel; T J Fields; J W Albright; T Diamantstein; J P Hughes
Journal:  Biochem J       Date:  1988-01-15       Impact factor: 3.857

9.  Interleukin 2 receptor-targeted cytotoxicity. Interleukin 2 receptor-mediated action of a diphtheria toxin-related interleukin 2 fusion protein.

Authors:  P Bacha; D P Williams; C Waters; J M Williams; J R Murphy; T B Strom
Journal:  J Exp Med       Date:  1988-02-01       Impact factor: 14.307

10.  Lymphokine and nonlymphokine mRNA levels in stimulated human T cells. Kinetics, mitogen requirements, and effects of cyclosporin A.

Authors:  A Granelli-Piperno; L Andrus; R M Steinman
Journal:  J Exp Med       Date:  1986-04-01       Impact factor: 14.307

View more
  10 in total

Review 1.  Perspectives in transplantation immunology 1991.

Authors:  D Kabelitz; M L da Silva Lobo; K Pechhold
Journal:  Klin Wochenschr       Date:  1991-09-03

2.  Leukotoxin kills rodent WBC by targeting leukocyte function associated antigen 1.

Authors:  Kristina M DiFranco; Rajesh H Kaswala; Chandni Patel; Chinnaswam Kasinathan; Scott C Kachlany
Journal:  Comp Med       Date:  2013-08       Impact factor: 0.982

3.  Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma.

Authors:  Peter Attia; Ajay V Maker; Leah R Haworth; Linda Rogers-Freezer; Steven A Rosenberg
Journal:  J Immunother       Date:  2005 Nov-Dec       Impact factor: 4.456

4.  Selective elimination of human regulatory T lymphocytes in vitro with the recombinant immunotoxin LMB-2.

Authors:  Peter Attia; Daniel J Powell; Ajay V Maker; Robert J Kreitman; Ira Pastan; Steven A Rosenberg
Journal:  J Immunother       Date:  2006 Mar-Apr       Impact factor: 4.456

5.  Diphtheria toxin-related cytokine fusion proteins: elongation factor 2 as a target for the treatment of neoplastic disease.

Authors:  J vanderSpek; L Cosenza; T Woodworth; J C Nichols; J R Murphy
Journal:  Mol Cell Biochem       Date:  1994-09       Impact factor: 3.396

6.  Partial reduction of human FOXP3+ CD4 T cells in vivo after CD25-directed recombinant immunotoxin administration.

Authors:  Daniel J Powell; Peter Attia; Victor Ghetie; John Schindler; Ellen S Vitetta; Steven A Rosenberg
Journal:  J Immunother       Date:  2008 Feb-Mar       Impact factor: 4.456

7.  Anti-leukemia activity of a bacterial toxin with natural specificity for LFA-1 on white blood cells.

Authors:  Scott C Kachlany; Amy B Schwartz; Nataliya V Balashova; Catarina E Hioe; Michael Tuen; Amy Le; Manpreet Kaur; Yongyi Mei; Jia Rao
Journal:  Leuk Res       Date:  2009-09-10       Impact factor: 3.156

8.  Differential effects of denileukin diftitox IL-2 immunotoxin on NK and regulatory T cells in nonhuman primates.

Authors:  Yohei Yamada; Akihiro Aoyama; Georges Tocco; Svjetlan Boskovic; Ognjenka Nadazdin; Alessandro Alessandrini; Joren C Madsen; A Benedict Cosimi; Gilles Benichou; Tatsuo Kawai
Journal:  J Immunol       Date:  2012-05-14       Impact factor: 5.422

9.  In vitro and in vivo studies of a VEGF121/rGelonin chimeric fusion toxin targeting the neovasculature of solid tumors.

Authors:  Liesbeth M Veenendaal; Hangqing Jin; Sophia Ran; Lawrence Cheung; Nora Navone; John W Marks; Johannes Waltenberger; Philip Thorpe; Michael G Rosenblum
Journal:  Proc Natl Acad Sci U S A       Date:  2002-06-11       Impact factor: 11.205

Review 10.  Bacteria-derived chimeric toxins as potential anticancer agents.

Authors:  Saeed Khoshnood; Hadis Fathizadeh; Foroogh Neamati; Babak Negahdari; Piyush Baindara; Mohd Azmuddin Abdullah; Mohammad Hossein Haddadi
Journal:  Front Oncol       Date:  2022-09-07       Impact factor: 5.738

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.